By contrast, hormone receptor positive (HR+)/HER2− BC is frequently referred to as immunologically “cold” as these tumors have both lower TIL densities and response rates to immunotherapy as compared with TNBC (3, 5). This evidence concerns the gene NR4A1 and breast cancer.